CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $865,000, lower than 95% of all stocks globally
- PositionOperating margin is -562900%, lower than 95% of its Biotechnology peers (median -23.8%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.77BUSDvs all stocks (USD)
Revenue (TTM)
865.00KUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.8970xvs all stocks
52-Week Change
60.24%vs all stocks
Market Capitalization
2.77BUSDvs all stocks (USD)
Enterprise Value
2.56BUSDvs all stocks (USD)
Forward P/E
-7.87xvs Biotechnology peers
Price to Book (MRQ)
5.17xvs Biotechnology peers
Enterprise to Revenue
2.96Kxvs Biotechnology peers
Enterprise to EBITDA
-8.37xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-30.89%vs Biotechnology peers
Return on Equity (TTM)
-48.94%vs Biotechnology peers
Revenue (TTM)
865.00KUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0130USDUpdated Jul 18, 2026Quarterly Revenue Growth
-97.80%vs Biotechnology peers
Gross Profit (TTM)
-264.60MUSDvs all stocks (USD)
EBITDA (TTM)
-305.70MUSDvs all stocks (USD)
Net Income (TTM)
-283.65MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-97.84%vs Biotechnology peers
Operating Cash Flow (TTM)
-222.16MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-126.27MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
1.54MUSDFY2025 · Dec 31, 2025Operating Income
-287.37MUSDvs all stocks (USD)
Pre-tax Income
-258.76MUSDFY2025 · Dec 31, 2025Net Income
-258.76MUSDFY2025 · Dec 31, 2025EBIT
-287.37MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-312.60MUSDFY2025 · Dec 31, 2025Research & Development
245.07MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
43.84MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-258.76MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-224.84MUSDFY2025 · Dec 31, 2025Free Cash Flow
-227.55MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
28.87MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-258.76MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.38MUSDFY2025 · Dec 31, 2025Stock-based Compensation
36.22MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.31MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.36MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.71MUSDFY2025 · Dec 31, 2025Purchase of Investments
-384.50MUSDFY2025 · Dec 31, 2025Sale of Investments
596.29MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
209.07MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
66.57MSharesUpdated Jul 18, 2026Shares Short
7.74MSharesUpdated Jul 18, 2026Short Ratio
5.97daysvs all stocks
Short % of Shares Outstanding
11.70%vs all stocks
% Held by Insiders
0.27%vs all stocks
% Held by Institutions
95.89%vs all stocks
Total Cash (MRQ)
451.46MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.75USDUpdated Jul 18, 2026Total Debt (MRQ)
1.91MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0042xvs Biotechnology peers
Current Ratio (MRQ)
8.92xvs Biotechnology peers
Book Value per Share (MRQ)
6.85USDUpdated Jul 18, 2026Total Assets
582.98MUSDvs all stocks (USD)
Total Current Assets
534.66MUSDFY2025 · Dec 31, 2025Total Liabilities
55.82MUSDFY2025 · Dec 31, 2025Total Non-current Assets
48.32MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.83MUSDFY2025 · Dec 31, 2025Total Current Liabilities
50.99MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
28.87MUSDFY2025 · Dec 31, 2025Other Short-term Investments
489.70MUSDFY2025 · Dec 31, 2025Accounts Receivable
2.02MUSDFY2025 · Dec 31, 2025Accounts Payable
1.18MUSDFY2025 · Dec 31, 2025Short-term Debt
1.55MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.23MUSDFY2025 · Dec 31, 2025Long-term Debt
784.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
4.04MUSDFY2025 · Dec 31, 2025Common Stock (Book)
67.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.81BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
527.16MUSDvs all stocks (USD)
52-Week Low
19.72USDUpdated Jul 18, 202652-Week High
40.30USDUpdated Jul 18, 202652-Week Change
60.24%vs all stocks
Beta
0.8970xvs all stocks
50-Day MA
33.25USDUpdated Jul 18, 2026200-Day MA
29.07USDUpdated Jul 18, 2026Avg 10-Day Volume
804.31KSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.13MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-4.27USDUpdated Jul 18, 2026Other Income / Expense
28.61MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -562900%, lower than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: -5,629Industry median: -0.24Industry P5: -32.91Peers compared: 197
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.76
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $865,000, lower than 95% of all stocks globallySignificant
Revenue (USD): 865,000Global P5: 30,274,777.221
Market cap is $2.77B, above the global median of $1.15BNotable
Market cap (USD): 2,774,694,745Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
uniQure N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Vera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Supernus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Double Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Joincare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beam Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
CanSino Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Trevi Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hypera S.A.
Tier 1ProductionApproval-Gated PipelineRule